Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic castration-resistant prostate cancer and a deleterious or suspected deleterious germline or somatic HRR gene alteration who progressed after enzalutamide or abiraterone.
LAMPGEN ANALYSIS
Why it matters
Extended PARP inhibition to an HRR-defined prostate cancer population after progression on androgen receptor-directed therapy.
What research teams should watch
Check that the alteration is among those covered by the label and capture the prior androgen receptor therapy.
PRIMARY RECORDS